感染

订阅

MedSci主页 / 所有栏目 / 感染

CLIN CHEM LAB MED：降钙素原在区分隐源性组织肺炎和社区获得性肺炎中的应用

2019-11-17 MedSci MedSci原创

肺炎降钙素原
关注

本研究旨在探讨炎症性生物标志物如白细胞(WBC)计数、c -反应蛋白(CRP)和降钙素原(PCT)在区分隐源性组织肺炎(COP)和社区获得性肺炎(CAP)中的作用。

本研究旨在探讨炎症性生物标志物如白细胞(WBC)计数、c -反应蛋白(CRP)和降钙素原(PCT)在区分隐源性组织肺炎(COP)和社区获得性肺炎(CAP)中的作用。

回顾性调查2010年1月至2017年12月在Kurashiki中心医院住院的COP患者的WBC计数、CRP和PCT水平，并将其结果与2010年10月至2017年11月前瞻性纳入的CAP患者的结果进行比较。将COP定义为特异性的组织病理学，可能的COP定义为在无特异性组织病理学发现或肺标本的情况下，胸部ct上的实变影和支气管肺泡灌洗液中淋巴细胞优势。通过ROC曲线分析，评价WBC计数、CRP和PCT的鉴别能力。

COP组共有56例病例，确证COP 35例(61.4%)，CAP 914例。三种生物标志物在COP中的AUC均显著低于CAP。PCT在所有COP患者中的AUC均为0.79，显著高于CRP (AUC 0.59, p < 0.001)和WBC (AUC 0.69, p = 0.048)。在确证的COP患者中，PCT的AUC值为0.79，显著高于WBC (AUC 0.64, p = 0.006)和CRP (AUC 0.64, p = 0.001)。

研究表明，PCT是一种比WBC计数或CRP更有用的区分COP和CAP的生物标志物。PCT应该作为临床表现和放射学发现的辅助手段。

原始出处：

Akihiro Ito，Tadashi Ishida，Utility of procalcitonin for differentiating cryptogenic organising pneumonia from community-acquired pneumonia

本文系梅斯医学（MedSci）原创编译整理，转载需授权！


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2042658, encodeId=445e20426580e, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Thu Aug 20 16:30:00 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277896, encodeId=ff6d12e78962f, content=<a href='/topic/show?id=464c98221e9' target=_blank style='color:#2F92EE;'>#降钙素原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98221, encryptionId=464c98221e9, topicName=降钙素原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d521144, createdName=wrj0121, createdTime=Tue Nov 19 12:30:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395848, encodeId=5c0a1395848b3, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Tue Nov 19 12:30:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610140, encodeId=912e16101407a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 19 12:30:00 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
    2020-08-20 pandamao2010

    #获得性#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2042658, encodeId=445e20426580e, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Thu Aug 20 16:30:00 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277896, encodeId=ff6d12e78962f, content=<a href='/topic/show?id=464c98221e9' target=_blank style='color:#2F92EE;'>#降钙素原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98221, encryptionId=464c98221e9, topicName=降钙素原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d521144, createdName=wrj0121, createdTime=Tue Nov 19 12:30:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395848, encodeId=5c0a1395848b3, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Tue Nov 19 12:30:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610140, encodeId=912e16101407a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 19 12:30:00 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
    2019-11-19 wrj0121

    #降钙素原#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2042658, encodeId=445e20426580e, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Thu Aug 20 16:30:00 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277896, encodeId=ff6d12e78962f, content=<a href='/topic/show?id=464c98221e9' target=_blank style='color:#2F92EE;'>#降钙素原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98221, encryptionId=464c98221e9, topicName=降钙素原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d521144, createdName=wrj0121, createdTime=Tue Nov 19 12:30:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395848, encodeId=5c0a1395848b3, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Tue Nov 19 12:30:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610140, encodeId=912e16101407a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 19 12:30:00 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
    2019-11-19 12498e67m28暂无昵称

    #社区#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2042658, encodeId=445e20426580e, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Thu Aug 20 16:30:00 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277896, encodeId=ff6d12e78962f, content=<a href='/topic/show?id=464c98221e9' target=_blank style='color:#2F92EE;'>#降钙素原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98221, encryptionId=464c98221e9, topicName=降钙素原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d521144, createdName=wrj0121, createdTime=Tue Nov 19 12:30:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395848, encodeId=5c0a1395848b3, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Tue Nov 19 12:30:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610140, encodeId=912e16101407a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 19 12:30:00 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
    2019-11-19 ms3994565386320060

    #Med#

    0

相关资讯

Blood：L-选择素脱落对肺内细菌清除-整合素-外-内信号通路的调控

革兰氏阴性菌引起的肺炎是一种常见的严重疾病，具有较高的发病率和死亡率。清除致病菌依赖于中性粒细胞的募集和功能。近期，研究发现黏附分子L-选择素参与中性粒细胞整合素活化(由内而外型信号传导)。但L-选择素参与宿主防御肺炎克雷伯菌引起的肺部炎症的分子机制尚不明确。

探案：淋巴瘤患者发热和气急1月，是感染吗？

女性，66岁，反复发热、气促1月余。

Crit Care：肺炎诱导的早期轻度急性呼吸窘迫综合征患者无创通气的疗效

由此可见，尽管NIV治疗可观察到PaO2/FIO2有所改善，但与标准氧气疗法相比，NIV治疗并不能减少肺炎诱发的早期轻度ARDS患者进行气管插管的需求。较高的每分钟通气量可能预示着NIV治疗失败。

隐原性机化性肺炎影像1例

头痛，全身酸痛伴咳嗽、咳白粘痰1月余，一周前出现畏寒，体温升至39度。

多次两肺炎症，来去匆匆，会是啥？

女性，46岁，江苏人，主诉：发现肺部阴影4月

联合国：肺炎成5岁以下儿童很大致死病因

联合国方面11月12日发布报告，显示去年全球超过80万名5岁以下儿童因感染肺炎死亡，即每39秒一名儿童死于肺炎。11月12日是世界肺炎日。联合国儿童基金会、国际慈善机构“救助儿童会”和另外4家卫生机构联合发布报告，敦促各国政府对肺炎疫苗、医疗服务及药物加大投资，以预防和治疗儿童肺炎。报告显示，去年全球80.2万名5岁以下儿童死于肺炎，占同年龄段因病死亡儿童的15%，远多于死于痢疾和疟疾的人数，后两